![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, March 26, 2022 1:04:36 PM
Nearly a year ago, Dr. Fauci touted ZYESAMI as a promising treatment for COVID-19. However, the drug appears no closer to receiving FDA approval. Meanwhile, treatments including remdesivir, Molnupiravir, Paxlovid and the COVID-19 vaccines were fast tracked to approval.
The members are seeking an explanation for the delayed review process and favoritism shown by federal health agencies for large drug manufacturers.
https://www.wispolitics.com/2022/u-s-sen-johnson-leads-colleagues-in-demanding-answers-from-dr-califf-and-dr-fauci/
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM